Contributions
Abstract: P1158
Type: Poster
Abstract Category: Therapy - disease modifying - Immunomodulation/Immunosuppression
Objectives: This study describes efficacy and safety of Fingolimod in patients treated for at least 6 months in the east of France from January 2011 to December 2014.
Background: The Grand-Est is a geographical region in France with a high prevalence of multiple sclerosis (more than 10000 patients registered in the European Database for Multiple Sclerosis EDMUS database). In this region and since January 2011, more than 1014 patients have been treated for at least 6 months with Fingolimod, the first oral therapy for patient with very active relapsing-remitting MS.
Methods: Features of patients followed up in the Grand-Est region and treated with fingolimod in the 6 university hospitals, general hospitals and private neurologists were reviewed in a retrospective study after identification of the clinical files reported in the EDMUS database.
Results: At inclusion: mean age of 29.7±9.4 years; sex ratio F/M 2.59; duration of MS: 10.8 ± 7.45 years; mean EDSS: 3.2±1.7; ARR: 0.8±0.9. Fingolimod was prescribed as a first line treatment in 20.12%, following immunomodulatory treatment in 49.3%, natalizumab in 31.16, and other treatment in 14.16%. Patients were treated for more than 2 years in 92%. Relapses were encountered in 20.8%. Mean time to the first relapse: (8.25 ±7.8 months). Annualized relapse rate was decreased by 83.75% after 1 year of treatment, and mean EDSS was stable after 1 year of treatment and increased by 0.1 after 2 and 3 years. EDSS increased more in patients experiencing relapses. Fingolimod was stopped in 17.42% of patients mainly because of adverse events (9.28%). Results were comparable among centers. Patients treated after 2013 were younger and exhibited lower levels of disability.
Conclusions: This is one of the largest real life series of patients treated with fingolimod in the east of France. The treatment seems well-tolerated and showed high efficacy on clinical activity after one year.
Disclosure:
Ayman Tourbah has received consulting and lecturing fees, travel grants and research support from Medday, Biogen Idec, Sanofi-Genzyme, Novartis, Merck Serono, Teva Pharma, and Roche
Eric Berger, Marc Debouverie, Jérôme De Sèze, served as consultant, board and therapeutical trials for Novartis
Thibault Moreau reports receiving consulting fees and speaking fees from Biogen Idec, Sanofi Aventis, Genzyme, Teva Pharma, Bayer Schering, Merck Serono, Roche, Almirall and Novartis, Roche.
Ludivine Chamard and Etienne Godet have nothing to disclose
Study supported by Novartis Pharma
Abstract: P1158
Type: Poster
Abstract Category: Therapy - disease modifying - Immunomodulation/Immunosuppression
Objectives: This study describes efficacy and safety of Fingolimod in patients treated for at least 6 months in the east of France from January 2011 to December 2014.
Background: The Grand-Est is a geographical region in France with a high prevalence of multiple sclerosis (more than 10000 patients registered in the European Database for Multiple Sclerosis EDMUS database). In this region and since January 2011, more than 1014 patients have been treated for at least 6 months with Fingolimod, the first oral therapy for patient with very active relapsing-remitting MS.
Methods: Features of patients followed up in the Grand-Est region and treated with fingolimod in the 6 university hospitals, general hospitals and private neurologists were reviewed in a retrospective study after identification of the clinical files reported in the EDMUS database.
Results: At inclusion: mean age of 29.7±9.4 years; sex ratio F/M 2.59; duration of MS: 10.8 ± 7.45 years; mean EDSS: 3.2±1.7; ARR: 0.8±0.9. Fingolimod was prescribed as a first line treatment in 20.12%, following immunomodulatory treatment in 49.3%, natalizumab in 31.16, and other treatment in 14.16%. Patients were treated for more than 2 years in 92%. Relapses were encountered in 20.8%. Mean time to the first relapse: (8.25 ±7.8 months). Annualized relapse rate was decreased by 83.75% after 1 year of treatment, and mean EDSS was stable after 1 year of treatment and increased by 0.1 after 2 and 3 years. EDSS increased more in patients experiencing relapses. Fingolimod was stopped in 17.42% of patients mainly because of adverse events (9.28%). Results were comparable among centers. Patients treated after 2013 were younger and exhibited lower levels of disability.
Conclusions: This is one of the largest real life series of patients treated with fingolimod in the east of France. The treatment seems well-tolerated and showed high efficacy on clinical activity after one year.
Disclosure:
Ayman Tourbah has received consulting and lecturing fees, travel grants and research support from Medday, Biogen Idec, Sanofi-Genzyme, Novartis, Merck Serono, Teva Pharma, and Roche
Eric Berger, Marc Debouverie, Jérôme De Sèze, served as consultant, board and therapeutical trials for Novartis
Thibault Moreau reports receiving consulting fees and speaking fees from Biogen Idec, Sanofi Aventis, Genzyme, Teva Pharma, Bayer Schering, Merck Serono, Roche, Almirall and Novartis, Roche.
Ludivine Chamard and Etienne Godet have nothing to disclose
Study supported by Novartis Pharma